Advertisement
Document › Details
Merck KGaA. (8/6/20). "Press Release: Leadership Change within Group Communications at Merck". Darmstadt.
Constantin Birnstiel (49), Head of Group Communications since 2017, is leaving Merck upon his own request. He is being succeeded with immediate effect by Thomas Möller (44). The company made this announcement today in conjunction with the publication of its half-year results.
“I cordially thank Constantin Birnstiel for his engagement and the results achieved in positioning Merck as a science and technology company as well as in purposefully advancing our communications activities. I wish him continued success and all the best,” said Stefan Oschmann, Chairman of the Executive Board and CEO of Merck. “Thomas Möller is an experienced communications professional with excellent knowledge of Merck. I am really looking forward to collaborating with him further.”
Constantin Birnstiel joined Merck in 2017 after having worked for Siemens, Osram, E.ON, and Uniper. The 350th anniversary celebrations, the divestment of the Consumer Health business and the acquisition of Versum Materials took place during his time as Head of Group Communications. Furthermore, Birnstiel was responsible for building the company's brand identity in China. Together with Möller, Birnstiel established Merck’s global newsroom, which was successfully launched in 2020. Over the past several years, the two have also resolutely driven the digitalization of Group Communications.
Thomas Möller joined Merck in 2017 and was most recently responsible for Corporate Communications. Before coming to Merck, he worked for BASF and held various Corporate Communications positions in Germany, the United States and Switzerland. Like his predecessor, he will report directly to Stefan Oschmann, Chairman of the Executive Board and CEO.
For more information, please contact Friederike Segeberg
+49 151 1454 6328
All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.
About Merck
Merck, a leading science and technology company, operates across healthcare, life science and performance materials. Around 57,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2019, Merck generated sales of € 16.2 billion in 66 countries.
Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials.
Record changed: 2023-06-05 |
Advertisement
More documents for Merck (DE) (Group)
- [1] Merck KGaA. (4/25/24). "Press Release: Merck Invests More Than € 300 Million in New Life Science Research Center in Germany". Darmstadt....
- [2] Caris Life Sciences Inc.. (4/4/24). "Press Release: Caris Life Sciences Announces Partnership with Merck KGaA, Darmstadt, Germany to Discover Novel Cancer Targets and Accelerate First-In-Class Antibody Drug Conjugate Development". Irving, TX....
- [3] BioGeneration Ventures B.V.. (4/2/24). "Press Release: BGV Appoints Peter Halle, PhD as Venture Partner". Amsterdam....
- [4] C4 Therapeutics, Inc.. (3/4/24). "Press Release: C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins". Watertown, MA....
- [5] ITM Isotope Technologies Munich SE. (12/14/23). "Press Release: ITM Executes License Agreement to Obtain Worldwide Exclusive License for the Clinical Development and Commercialization of Folate-Based Radiotheranostics". Garching....
- [6] Merck KGaA. (12/4/23). "Press Release: Merck Strengthens Oncology Portfolio through Commercialization Agreement With Abbisko for Phase III Asset, Pimicotinib [Not intended for UK-, US- or Canada-based media]". Darmstadt....
- [7] Merck KGaA. (11/21/23). "Press Release: Merck Expands Newest Biologics Testing Center in Shanghai". Shanghai....
- [8] Merck KGaA. (11/14/23). "Press Release: Merck Announces Plans for New U.S. Healthcare Headquarters in Boston’s Seaport District [Not intended for US-based media]". Darmstadt....
- [9] Merck KGaA. (10/30/23). "Press Release: Merck Strengthens Oncology Pipeline Through Strategic Partnership with Hengrui for Next-Generation Selective PARP1 Inhibitor and Antibody-Drug Conjugate [Not intended for US-, Canada- or UK-based media]". Darmstadt...
- [10] Exscientia plc. (10/3/23). "Press Release: Exscientia Details Pipeline Prioritisation Strategy". Oxford....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top